Kallisio is revolutionizing cancer care with innovative medtech solutions that empower oncologists to manage treatment-related toxicity and safeguard patients throughout their cancer journey. By developing advanced technologies customized to each patient’s unique anatomy and treatment needs, Kallisio ensures precise therapy delivery while protecting healthy tissues across multiple treatment modalities.
The stentra™ oral stent, a 3D-printed, patient-specific device, exemplifies this approach. It provides unparalleled protection for Organs-at-Risk (OARs) during cancer therapy, significantly reducing side effects like oral mucositis. This results in better patient outcomes, enhanced comfort, and improved quality of life during treatment.
Through its commitment to precision, innovation, and patient-centered care, Kallisio transforms oncology treatment, enabling clinicians to deliver safer, more effective therapies while reducing the burden of cancer toxicity.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2022
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was kallisio,inc. founded?
kallisio,inc. was founded in 2022.
What industry is kallisio,inc. in?
kallisio,inc. operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is kallisio,inc. based?
kallisio,inc. is headquartered in Baltimore, United States.
Find investors for your startup like kallisio,inc.
Gritt sends AI-personalised outreach to each investor — from your Gmail
